TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11782033

Group type: EXPERIMENTAL
Intervention: Bayesian monitoring and analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Archetypal prior distributions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular reporting of priors, likelihoods, and posterior distributions
Number of subjects: 0
Study: 9839827

Group type: EXPERIMENTAL
Intervention: Capsaicin cream (0.025%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GTN cream (1.33%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: GTN cream (1.33%) + Capsaicin cream (0.025%)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7527418

Group type: EXPERIMENTAL
Intervention: Glucose polymer solution (trial G)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (trial C)
Number of subjects: 4
Study: 2734422

Group type: EXPERIMENTAL
Intervention: Laboratory cognitive stressor (mental arithmetic)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Components of verbal competition and loudness of voice
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Laboratory hyperreactivity
Number of subjects: 33
Study: 29754580

Group type: EXPERIMENTAL
Intervention: Health Oriented Pedagogical Project (HOPP) intervention consisting of 45 minutes of physical activity a day for 6-8 months in addition to regular physical education lessons.
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1173
Study: 27306256

Group type: EXPERIMENTAL
Intervention: Individualized physical therapy (10 sessions)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Guideline-based advice (2 sessions)
Number of subjects: 300
Study: 26575036

Group type: EXPERIMENTAL
Intervention: Nebulized epinephrine plus 3% hypertonic saline
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo plus 3% hypertonic saline
Number of subjects: 208
Study: 25328957

Group type: EXPERIMENTAL
Intervention: Integrated cognitive behaviour therapy (CBT) for PTSD and AUD (IT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: CBT for AUD plus supportive counselling (AS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Alcohol-support (AS)
Number of subjects: 62
Study: 21556834

Group type: COMPARATOR
Intervention: Insulin-stimulated glucose uptake in adipose tissue
Number of subjects: 15

Group type: COMPARATOR
Intervention: Insulin-mediated suppression of lipolysis and adiponectin metabolism
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hepatic fat content
Number of subjects: 15

Group type: COMPARATOR
Intervention: Hepatic glucose metabolism
Number of subjects: 15
Study: 18085502

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) treatment for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo treatment for 6 months
Number of subjects: 60
Study: 16530965

Group type: EXPERIMENTAL
Intervention: Painful stimulation (venipuncture)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tactile stimulation (skin disinfection)
Number of subjects: 40
Study: 14598874

Group type: EXPERIMENTAL
Intervention: Lercanidipine
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 87
Study: 15572462

Group type: COMPARATOR
Intervention: IVF treatment phases (4 distinct stages)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pregnancy (second trimester)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pregnancy (third trimester)
Number of subjects: 75
Study: 10490250

Group type: EXPERIMENTAL
Intervention: CharcoAid G (CA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LiquiChar (LC)
Number of subjects: 60
Study: 8942419

Group type: EXPERIMENTAL
Intervention: Vitamin A (1000 RE/d) for 30 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: COPD-moderate-severe and COPD-moderate-severe+ex groups
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Healthy smokers and COPD-mild patients
Number of subjects: 36
Study: 2017645

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily) for 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g once daily for 2 weeks) followed by oral amoxicillin (1 g four times a day for 2 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ceftriaxone (2 g once daily) for 4 weeks and Ceftriaxone followed by amoxicillin
Number of subjects: 30
Study: 6124760

Group type: EXPERIMENTAL
Intervention: Biosynthetic human insulin (BHI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Bovine insulin
Number of subjects: 94

Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 94
Study: 31602579

Group type: EXPERIMENTAL
Intervention: Incomplete Cytoreduction Risk Score (ICRS) derived from preoperative factors
Number of subjects: 2027

Group type: EXPERIMENTAL
Intervention: ICRS applied to validation cohort
Number of subjects: 2027
Study: 28139512

Group type: EXPERIMENTAL
Intervention: Shikani Optical Stylet (SOS)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Macintosh Laryngoscope (MLS)
Number of subjects: 270
Study: 25734456

Group type: EXPERIMENTAL
Intervention: Nonwoven porous adhesive bandage (NPAB)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Transparent film adhesive bandage (TFAB)
Number of subjects: 300
Study: 25041859

Group type: EXPERIMENTAL
Intervention: Weekly adalimumab dosing
Number of subjects: 248

Group type: COMPARATOR
Intervention: Every other week (EOW) adalimumab dosing
Number of subjects: 248
Study: 22241056

Group type: EXPERIMENTAL
Intervention: 400 IU/kg rHuEpo
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18389368

Group type: EXPERIMENTAL
Intervention: Supervised resistance exercise
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise
Number of subjects: 242

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 242
Study: 17288659

Group type: EXPERIMENTAL
Intervention: Home telecare group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15145810

Group type: EXPERIMENTAL
Intervention: Local false discovery rate (local FDR) estimation using a mixture model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proposed mixture model for estimating local FDR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estimation of the proportion of differentially expressed genes, pFDR, negative predictive values, sensitivity, and specificity
Number of subjects: 0
Study: 12536508

Group type: EXPERIMENTAL
Intervention: Insulin and hyperosmotic glucose solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moist burn ointment (Control)
Number of subjects: 0
Study: 9891833

Group type: EXPERIMENTAL
Intervention: Primary prevention (Group I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary prevention (Group II)
Number of subjects: 0
Study: 8296730

Group type: EXPERIMENTAL
Intervention: Fixed-wire (FW) system
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Over-the-wire (OW) system
Number of subjects: 602
Study: 2662674

Group type: EXPERIMENTAL
Intervention: Venoruton
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 15
Study: 31525187

Group type: EXPERIMENTAL
Intervention: SLATE algorithm
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1077
Study: 27905102

Group type: EXPERIMENTAL
Intervention: Decitabine (DAC)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pre-treatment elevated HbF
Number of subjects: 52
Study: 26451070

Group type: EXPERIMENTAL
Intervention: High-dose vitamin D (4000 IU/d)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose vitamin D (400 IU/d)
Number of subjects: 40
Study: 24079908

Group type: EXPERIMENTAL
Intervention: Storybook intervention (The Tale of Woody's Tonsils)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no storybook)
Number of subjects: 80
Study: 21266950

Group type: EXPERIMENTAL
Intervention: Abdominal adiposity, waist circumference (WC), and body mass index (BMI)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Obesity measures
Number of subjects: 112
Study: 21056842

Group type: EXPERIMENTAL
Intervention: Chinese herbs extra group (CH) with complementary therapies of Chinese medicine and standard treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard treatment only group (ST)
Number of subjects: 32
Study: 17384341

Group type: EXPERIMENTAL
Intervention: Individual initiation of bedtime insulin glargine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Group initiation of bedtime insulin glargine
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 121
Study: 15872078

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 11907427

Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 0
Study: 10393380

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 31
Study: 7572013

Group type: EXPERIMENTAL
Intervention: 0.4 mg buprenorphine (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 40
Study: 2322621

Group type: EXPERIMENTAL
Intervention: Ethanol (0.8 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcoholic beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alcoholic drink
Number of subjects: 0
Study: 6894099

Group type: EXPERIMENTAL
Intervention: tolamolol 200 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: diazepam 10 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 31944502

Group type: EXPERIMENTAL
Intervention: M4 regimen (2R7 H7 Z7 E7 M7 /2R3 H3 M3)
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Control regimen (2H3 R3 Z3 E3 /4R3 H3)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: M4-I regimen (2R7 H7 Z7 E7 M7 /2R3 H3 E3 M3)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: M4-IE regimen (2R7 H7 Z7 E7 M7 /2R3 H3 M3)
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Moxifloxacin regimens
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Control regimen
Number of subjects: 1371
Study: 31806605

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 70

Group type: COMPARATOR
Intervention: Corticosteroid/alkylating-agent therapy
Number of subjects: 70
Study: 27720359

Group type: EXPERIMENTAL
Intervention: Swiss ball training exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Frenkel exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 60
Study: 25465978

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study: 23433349

Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants for 12 months
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Health coaching by medical assistants
Number of subjects: 441
Study: 21812663

Group type: EXPERIMENTAL
Intervention: Lebrikizumab
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Lebrikizumab (high-periostin subgroup)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Lebrikizumab (low-periostin subgroup)
Number of subjects: 219
Study: 19627292

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study: 16769946

Group type: EXPERIMENTAL
Intervention: Scale for the Assessment and Rating of Ataxia (SARA)
Number of subjects: 286
Study: 15311105

Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg) and antihypertensive drugs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Antihypertensive drugs only (Control group)
Number of subjects: 34
Study: 11707629

Group type: EXPERIMENTAL
Intervention: Alcohol administration
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 32
Study: 8988115

Group type: EXPERIMENTAL
Intervention: Topical 0.2% GTN ointment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7691557

Group type: EXPERIMENTAL
Intervention: Topographical mapping of EEG during motor task
Number of subjects: 24

Group type: COMPARATOR
Intervention: Topographical mapping of EEG during eyes open conditions
Number of subjects: 24
Study: 3300569

Group type: EXPERIMENTAL
Intervention: Hydrolysed wheat ORS
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Rice ORS
Number of subjects: 78

Group type: COMPARATOR
Intervention: Glucose ORS
Number of subjects: 78
Study: 30451888

Group type: EXPERIMENTAL
Intervention: Mavoglurant (up to 100 mg bid for up to 34 months)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Placebo (from core studies)
Number of subjects: 267
Study: 26566638

Group type: EXPERIMENTAL
Intervention: Tönnis classification assessment by three orthopaedic surgeons
Number of subjects: 61
Study: 24920884

Group type: EXPERIMENTAL
Intervention: High dose (fluticasone 1,000 μg + salmeterol 100 μg/day)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Medium dose (fluticasone 500 μg + salmeterol 100 μg/day)
Number of subjects: 237
Study: 22383318

Group type: EXPERIMENTAL
Intervention: Symax(TM) uncemented stem
Number of subjects: 49

Group type: COMPARATOR
Intervention: Omnifit(®) uncemented stem
Number of subjects: 49
Study: 20502447

Group type: EXPERIMENTAL
Intervention: Pancrelipase (72,000 lipase units per meal; 36,000 per snack)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pancrelipase
Number of subjects: 54
Study: 18700898

Group type: EXPERIMENTAL
Intervention: Parnaparin-MMX (70, 140, and 210 mg once daily) for 8 weeks
Number of subjects: 10
Study: 15191507

Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12370870

Group type: EXPERIMENTAL
Intervention: Body weight-supported treadmill training (BWSTT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional physical therapy (PT)
Number of subjects: 24
Study: 9695205

Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution rinsing 4 times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sterile water rinsing (Control)
Number of subjects: 40
Study: 8122604

Group type: EXPERIMENTAL
Intervention: dl-sotalol 80 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: dl-sotalol 160 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: digoxin monotherapy (placebo)
Number of subjects: 60
Study: 2486654

Group type: COMPARATOR
Intervention: Morphine hydrochloride (50 micrograms/kg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Buprenorphine hydrochloride (3 micrograms/kg)
Number of subjects: 40
Study: 700598

Group type: EXPERIMENTAL
Intervention: Trospium chloride (oral application)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trospium chloride (parenteral application)
Number of subjects: 0
Study: 31773776

Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 4

Group type: COMPARATOR
Intervention: Rotenone-exposed
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Rotenone + Melatonin
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control
Number of subjects: 4
Study: 31699751

Group type: EXPERIMENTAL
Intervention: Study-approved lotion
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Study-approved cream
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Study-approved gel
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Study-approved ointment
Number of subjects: 520

Group type: COMPARATOR
Intervention: Standard care (topical corticosteroids)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Eczema signs (Eczema Area Severity Index) by masked researcher
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Treatment use
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Parent satisfaction
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Child and family quality of life (Atopic Dermatitis Quality of Life, Child Health Utility 9D and Dermatitis Family Impact)
Number of subjects: 520
Study: 28076735

Group type: EXPERIMENTAL
Intervention: Medication management plans completed by a pharmacist (intervention)
Number of subjects: 832

Group type: COMPARATOR
Intervention: Standard medical discharge summaries (control)
Number of subjects: 832
Study: 25817213

Group type: EXPERIMENTAL
Intervention: Endodontic treatment and scaling and root planning (SRP) performed simultaneously
Number of subjects: 31

Group type: COMPARATOR
Intervention: SRP performed 3 months after endodontic treatment
Number of subjects: 31
Study: 23980077

Group type: EXPERIMENTAL
Intervention: FOLFOX4
Number of subjects: 371

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 371
Study: 21613350

Group type: EXPERIMENTAL
Intervention: 7-h GH infusion (0.2-0.3 mg in total) that terminated 5 h before the clamp (study 1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 7-h GH infusion timed to continue during the first hour of the clamp (study 2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: No GH (study 0)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (healthy untreated subjects)
Number of subjects: 8
Study: 19357559

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection after cataract surgery
Number of subjects: 26

Group type: COMPARATOR
Intervention: Balanced salt solution injection (Control)
Number of subjects: 26
Study: 17110056

Group type: EXPERIMENTAL
Intervention: Interactive computer-assisted instruction program
Number of subjects: 344

Group type: COMPARATOR
Intervention: Culturally appropriate video
Number of subjects: 344

Group type: COMPARATOR
Intervention: Pamphlet only
Number of subjects: 344

Group type: COMPARATOR
Intervention: Non-interactive group (pamphlet and video combined)
Number of subjects: 344
Study: 15501376

Group type: EXPERIMENTAL
Intervention: Enhanced version of usually provided services
Number of subjects: 179

Group type: COMPARATOR
Intervention: Usually provided services
Number of subjects: 179
Study: 11707669

Group type: EXPERIMENTAL
Intervention: Tenofovir DF plus Hydroxyurea (500 mg bid for 28 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tenofovir DF (75 mg once daily for 28 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Tenofovir placebo
Number of subjects: 28
Study: 9140907

Group type: EXPERIMENTAL
Intervention: Steady-state exercise (150 min at 58% of PPO)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Stochastic exercise (150 min at 58 +/- 12.2% of PPO)
Number of subjects: 6
Study: 8198302

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 1%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diphenhydramine 2%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lidocaine 1%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 24
Study: 3805550

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Albuterol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Albuterol
Number of subjects: 18
Study: 31505955

Group type: EXPERIMENTAL
Intervention: Hard palate closure at age 12 months
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Hard palate closure at age 36 months
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Posterior cleft width
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cleft size at tuberosity level
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Anteroposterior palatal length
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Pooled scores VPC-Pooled
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Dichotomic scores VPC-Dichotomic
Number of subjects: 125
Study: 29471763

Group type: EXPERIMENTAL
Intervention: Behavioral HIV/STI intervention (Women on the Road to Health [WORTH])
Number of subjects: 333
Study: 27776678

Group type: EXPERIMENTAL
Intervention: PM plus cognitive behavioral therapy (CBT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: PM only
Number of subjects: 140
Study: 24684603

Group type: EXPERIMENTAL
Intervention: ta‐VNS
Number of subjects: 144

Group type: COMPARATOR
Intervention: tn‐VNS
Number of subjects: 144
Study: 23789813

Group type: EXPERIMENTAL
Intervention: Bolus saline injection with arm elevation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no saline injection)
Number of subjects: 30
Study: 20463310

Group type: EXPERIMENTAL
Intervention: Upper punctal occlusion
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lower punctal occlusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 40
Study: 18249220

Group type: EXPERIMENTAL
Intervention: Dietary glycemic index (GI)
Number of subjects: 18137

Group type: EXPERIMENTAL
Intervention: Dietary glycemic load (GL)
Number of subjects: 18137
Study: 16774830

Group type: EXPERIMENTAL
Intervention: Intrathecal hyperbaric bupivacaine 3.75 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intrathecal hyperbaric bupivacaine 9 mg
Number of subjects: 44
Study: 14516015

Group type: EXPERIMENTAL
Intervention: Behavioral interventions for HIV prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Experimental studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New program of research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials
Number of subjects: 0
Study: 11206018

Group type: EXPERIMENTAL
Intervention: Routine invasive strategy (cardiac catheterization followed by percutaneous coronary intervention within 24 hours of onset of angina)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative (ischemia-guided) strategy with aggressive medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment (intensive antiplatelet, antithrombotic, and anti-ischemic therapy)
Number of subjects: 0